Drug application
VIGABATRIN (VIGABATRIN)
Drugs@FDA ANDA 212626 · SPECGX LLC
Key facts
| Drug name | VIGABATRIN |
|---|---|
| Active ingredients | VIGABATRIN |
| Application type | ANDA |
| Application number | 212626 |
| Company | SPECGX LLC |
| Dosage forms | FOR SOLUTION, ORAL |
| Strength | 500MG/PACKET |
| Marketing status | Discontinued |
| Reference listed drug | No |
| Latest submission status date | Jul 28, 2021 |
At a glance
- 1–9 Submissions
- 1–9 Supplements
- None Label versions
- 1–9 Products
- None Therapeutic equivalents
- No FDA letters on file
- No FDA reviews on file
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA applications
Drugs@FDA covers FDA-approved brand-name and generic drugs and therapeutic biologics, with their applications (NDA, ANDA or BLA), products, submissions and labels.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA · Source date: